Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
227 enrolled
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
Phase NA Terminated
17 enrolled
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Phase 1 Terminated
28 enrolled
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
Phase 2 Terminated
3 enrolled 11 charts
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled 43 charts
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
Phase 1 Terminated
4 enrolled
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
Phase 1 Terminated
12 enrolled
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
Phase 1/2 Terminated
8 enrolled 13 charts
A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Phase 1 Terminated
11 enrolled
O-Mel-Inib
Phase 2 Terminated
13 enrolled
Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response
Phase NA Terminated
28 enrolled
PORTSIDE
Phase 2 Terminated
38 enrolled
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Phase 1 Terminated
29 enrolled
Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry
Phase NA Terminated
3 enrolled
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Phase 2 Terminated
1 enrolled
Preventing Lymphedema in Axillary Lymph Node Dissection
Phase NA Terminated
264 enrolled
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Phase 3 Terminated
52 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
Tamarack
Phase 2 Terminated
192 enrolled 20 charts
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Phase 1/2 Terminated
46 enrolled 22 charts
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
45 enrolled 44 charts
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
Phase 1 Terminated
12 enrolled
EPITOP-01
Phase 4 Terminated
40 enrolled
RELATIVITY-098
Phase 3 Terminated
1,093 enrolled 15 charts
PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors
Phase 2 Terminated
3 enrolled 7 charts
KZR-261 in Subjects With Advanced Solid Malignancies
Phase 1 Terminated
61 enrolled 25 charts
Pembrolizumab and EDP1503 in Advanced Melanoma
Phase 2 Terminated
8 enrolled 10 charts
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study
Phase 1 Terminated
3 enrolled
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Phase 2 Terminated
18 enrolled
APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma
Phase 1/2 Terminated
34 enrolled 18 charts
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Phase 1/2 Terminated
31 enrolled
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
A Study of ASP1012 in Adults With Solid Tumors
Phase 1 Terminated
15 enrolled
PAVO
Phase 2 Terminated
22 enrolled 17 charts
MAVIS
Phase 3 Terminated
504 enrolled 23 charts
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Phase 1 Terminated
65 enrolled 52 charts
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
Phase 1/2 Terminated
31 enrolled 12 charts
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
31 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
YASU Research Registry: For Young Adults With Cancer
Terminated
192 enrolled
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Phase 2 Terminated
23 enrolled 15 charts
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Phase 1 Terminated
75 enrolled
COMBI-i
Phase 3 Terminated
568 enrolled 28 charts
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Phase 2/3 Terminated
20 enrolled 18 charts
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1 Terminated
88 enrolled
E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma
Phase 1 Terminated
13 enrolled
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Phase 1 Terminated
44 enrolled
7T MRI Scan for the Early Detection of Melanoma Brain Metastases
Phase NA Terminated
2 enrolled
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
Phase NA Terminated
15 enrolled